Alembic Pharma receives approval for Fenofibric Acid Capsules
Sanket Dewarkar / 15 May 2017
Leading pharma company, Alembic Pharmaceuticals Ltd has said that the company has received approval from the US Food & Drug Administration for its Abbreviated New Drug Application for Fenofibric Acid Delayed-Release Capsules
Leading pharma company, Alembic Pharmaceuticals Ltd has said that the company has received approval from the US Food & Drug Administration for its Abbreviated New Drug Application for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg.
“The approved ANDA is therapeutically equivalent to the reference listed drug product Trilipix Delayed Release Capsules, 45 mg and 135 mg of Abbvie Inc,” the company said in a filing to the Bombay Stock Exchange.
Alembic has total of 56 ANDA approvals (50 final approvals and 6 tentative approvals) from USFDA
Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India.
Meanwhile on today’s trade Alembic Pharmaceuticals Ltd has opened at Rs.602 and touched a high of Rs.614.20, and on 10:36 am the stock is quoting at Rs.592.90 per share.